PRMT1 and lung carcinoma: Targeting the PRMT1/PRMT6 heteromer could create a new class of PRMT inhibitors in treating lung cancer to overcome the current limitations of PRMT1 or PRMT6 inhibitors, thereby opening up new horizons for efficacious PRMT1/PRMT6-targeted agents that are expected to eliminate lung cancer health disparities.